Clinical Trial News

FDA approves Eli Lilly's Zepbound, a GLP-1 weight-loss drug, for treating moderate to severe obstructive sleep apnea in adults with obesity, marking the first drug treatment option for certain patients with OSA. Zepbound, also known as tirzepatide, significantly improves OSA and aids in long-term weight loss, with nearly half of clinical trial patients no longer experiencing OSA symptoms.

The FDA granted Jemperli (dostarlimab-gxly) a breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, marking its second designation for this population. Jemperli showed a 100% clinical complete response rate in a phase 2 trial, supporting its potential to improve treatment for patients with this condition.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. The drug, used with a reduced-calorie diet and exercise, helps reduce OSA symptoms by aiding weight loss, as shown in 52-week studies. This approval reflects growing interest in weight loss drugs for conditions beyond obesity and diabetes.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including breathing pauses, compared to a placebo. The approval marks a significant advancement for OSA patients.

Jefferies analyst Peter Welford anticipates Novo Nordisk shares to drop at least 10%-15% due to disappointing Phase III CagriSema obesity data, showing 20.4% weight loss and potential tolerability issues. The firm maintains an Underperform rating with an $81.50 price target.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including breathing pauses, compared to a placebo. The approval marks a significant advancement for OSA patients.

Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including shallow breathing episodes. The approval reflects growing interest in weight loss drugs for conditions beyond obesity and diabetes.

The FDA authorized Zepbound, a weight loss drug by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea (OSA). Studies showed Zepbound reduced OSA symptoms, with significant reductions in breathing pauses compared to a placebo. The drug is used with a reduced-calorie diet and exercise.

A 57-year-old woman with cirrhosis, Crohn disease, and chronic hepatitis B presented with abdominal pain and fatigue. Diagnosed with stage IV hepatocellular carcinoma (HCC), she was treated with lenvatinib due to her autoimmune disease. Lenvatinib was supported by the REFLECT trial, showing noninferior overall survival and superior progression-free survival compared to sorafenib. The patient had a partial response initially but discontinued treatment due to disease progression. Observational data suggest lenvatinib may be favorable for Child-Pugh B patients.

FDA approves Pfizer's BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. Based on BREAKWATER trial, the combination showed significant improvement in response rate and durability. This is the first BRAF-targeted therapy regimen for first-line treatment of BRAF V600E-mutant mCRC.